Abbott Laboratories
ABT NYSEAbbott Laboratories looks about 18% undervalued against its cash-flow value. Its growth outlook scores strong; the balance sheet is solid.
No single event this week: ~₹10.1K–10.9K a share on Otto's scenarios, depending on the weights.
On consensus ABT trades at ~18.1x next year's earnings. Otto's scenarios weight out to ~₹10.1K–10.9K as the mix shifts from bear-leaning to bull-leaning; the price, ₹9,957, sits below that. Outcomes run ~₹6,495 to ~₹14.6K.
01 · Forward P/E
- ABT ~18.1x
Next fiscal year's consensus earnings. P/E ÷ growth: ABT ~0.15.
02 · Scenario weights
| Mix | Weighted | At 8–10% |
|---|---|---|
| 40/45/15 Bull-leaning | ~₹10.9K | ~₹9,372–13.0K |
| 25/50/25 Balanced (Otto's lean) | ~₹10.5K | ~₹9,014–12.5K |
| 15/45/40 Bear-leaning | ~₹10.1K | ~₹8,665–12.0K |
No results, sharp move or standout headline in the last week. Otto keeps the balanced mix.
03 · The range, a share
Bars span a 8–10% discount rate.
- Stress ~₹6,495–8,912
- Bear ~₹7,647–10.5K
- Base ~₹8,967–12.4K
- Bull ~₹10.5K–14.6K
- Analyst targets ~₹9,267–12.0K
- Weighted ~₹10.1K–10.9K
Current price ₹9,957.
- ~18.1x
- Forward P/E, consensus
- ~0.15
- P/E per point of EPS growth
- ~₹6,495–14.6K
- Full range, stress to bull
- ₹9,957
- Price: below the weighted range
- ~₹10.1K–10.9K
- Weighted, bear- to bull-leaning
Forward P/E and analyst targets: Yahoo Finance consensus. Scenarios: Otto's cash-flow model with growth from +7% to +19% a year and a discount rate of 8–10% — arithmetic on reported results, not a forecast. Not investment advice — Otto just crunches numbers.
At a glance
tap a tile to dig inOtto's verdict
the tiles above, in a line each- Value Looks ~18% undervalued against Otto's cash-flow estimate.
- Health 16 of 21 health checks pass.
- Growth Revenue trend ≈ +9%/yr (extended trend, not a forecast).
- Street Analysts lean buy · avg target +11% from here.
- Dividend Pays a dividend — yields 2.35%.
- Insiders Insiders, last 12 months: 2 buys · 0 sells.
Not investment advice — Otto just crunches numbers.
Price trend
+18.8% over six months · S&P 500 -8.1%
What think
The market's move: +18.8% over the past year
Trading 51% up its 52-week range. Price is the market's live vote — not advice.
Analyst consensus: Buy · 26 analysts
Average 12-month target ₹11,019.14 — +10.7% vs today.
Yahoo Finance's analyst aggregate. Sentiment, not advice.
Insiders: 2 buys · 0 sales in recent filings
Open-market trades from SEC Form 4. Sales are often pre-planned (10b5-1); buys tend to say more. Sentiment, not advice.
InvestRight readers: 0 watching
This site's own activity — not a broad measure. Sentiment, not advice.
The snowflake
checks passed on each axis- Value 1/2 checks
- Future 4/4 checks
- Past 2/4 checks
- Health 4/5 checks
- Dividend 5/6 checks
What does this show?
Five quick health scores — Value, Future, Past, Health and Dividend — each 0–100%. A bigger, more even shape means a stock that scores well across the board; a spiky one is strong on some axes and weak on others.
Learn more on Investopedia →Fair value
our estimate · not analyst forecast18% below our estimate — you'd be paying less than our numbers say it's worth.
How we got there
A 2-stage discounted-cash-flow on free cash flow: grow it at the capped historical trend for five years, fade to a 2.5% long-run rate, discount everything at 9.0%. It's a transparent estimate from past numbers, not a licensed forecast — treat it as one lens, not truth.
What does this show?
Our estimate of what one share is worth based on the cash the business is expected to generate (a discounted-cash-flow model), next to today's price. Below fair value hints undervalued, above hints expensive — it's an estimate, not a guarantee.
Learn more on Investopedia →Health checks
21 checks run on free data- ⚠ Debt is under 40% of equity debt/equity 65%
- ⚠ Growth accelerating vs its average latest -51.3%/yr vs 18.6% average
- ⚠ Return on equity above 20% ROE 12.3%
- ⚠ More than 20% below fair value +18% margin of safety
- ⚠ Yield in the top quartile of payers yield 2.65% vs 5.05% cut among the 13 payers Otto tracks
- ✓ Trading below our fair-value estimate +18% vs our DCF estimate
Show all 21 checks by axis
Value 1/2 passed
- ✓ Trading below our fair-value estimate +18% vs our DCF estimate
- – P/B below industry industry P/B not on the free feed
- – P/E below industry industry P/E not on the free feed
- – P/E below peer average peer P/Es land after the next refresh
- – P/S sane vs its own history needs multi-year P/S (Tier B)
- ⚠ More than 20% below fair value +18% margin of safety
Future 4/4 passed
- ✓ Earnings trending up 18.6%/yr over 9yr
- – Growth beats the industry industry growth not on the free feed
- ✓ Earnings growth beats the market 18.6%/yr vs market ~9.0%
- ✓ Revenue trending up 8.7%/yr over 9yr
- ✓ Return on equity improving ROE 12.5% vs 6.8% 9yr ago
Past 2/4 passed
- ✓ Earnings grew over the period 1.4B → 6.5B
- – High-quality earnings (few one-offs) one-off detection deferred — needs statement detail
- ⚠ Growth accelerating vs its average latest -51.3%/yr vs 18.6% average
- ✓ Revenue higher than five years ago 20.9B → 44.3B
- ⚠ Return on equity above 20% ROE 12.3%
Health 4/5 passed
- ✓ Debt/equity falling over time long-term debt/equity 19.0% vs 100.7%
- ⚠ Debt is under 40% of equity debt/equity 65%
- ✓ Debt well covered by cash flow operating cash flow covers 74.0% of debt
- ✓ Interest comfortably covered by profit EBIT covers interest 16.3×
- – Short-term assets cover long-term debt n/a
- ✓ Short-term assets cover short-term bills 26.0B vs 16.5B
Dividend 5/6 passed
- ✓ Dividend covered by earnings and cash flow covered by both earnings and free cash flow
- ✓ Dividend growing over time over 10yr on record
- ✓ No dividend cut in recent years steady over 10yr on record
- ✓ Payout ratio under 75% payout 67.2% of earnings
- ✓ Yield beats the market yield 2.65% vs market ~1.5%
- ⚠ Yield in the top quartile of payers yield 2.65% vs 5.05% cut among the 13 payers Otto tracks
What does this show?
Pass/fail rules on the company's finances — debt levels, profitability, cash cover and so on. More greens means a sturdier balance sheet; an n/a just means we didn't have that data point.
Learn more on Investopedia →Past performance
10-yr history from SEC EDGAR filingsRevenue
Earnings
Free cash flow
dashed line = what it'd look like growing at our ~9% market-average benchmark, for comparison
What does this show?
How revenue, earnings and free cash flow have grown over the years. Bars rising left-to-right show a growing business; the dashed line is a market-average pace for comparison.
Learn more on Investopedia →Future
trend, not analyst forecastRevenue · extended at 8.7%/yr
Earnings · extended at 15.0%/yr
Dashed bars just extend the historical trend (capped at ±15%/yr) — the same growth our DCF uses. It's arithmetic on the past, not an analyst forecast; real futures bend.
What does this show?
Solid bars are history; dashed bars simply extend the past growth trend a few years forward — capped so it stays sane. It's a trend line, not an analyst forecast.
Learn more on Investopedia →Dividend
from cash actually paid, not promisesTotal dividends paid · split-proof, unlike per-share history
What does this show?
The share of profit paid back to shareholders as cash. Yield is that cash as a % of the price; the payout gauge shows how much of earnings is paid out (over ~75% can be hard to sustain).
Learn more on Investopedia →Ownership & insiders
from SEC Form 4 filings2 open-market buys · 0 sales in the last 8 saved filings
- Tax-withhold Morrone Louis H. · EXECUTIVE VICE PRESIDENT 269 sh · ₹2.31M 2026-06-30
- Tax-withhold Cushman Elizabeth C. · EVP, GC AND SECRETARY 560 sh · ₹4.88M 2026-06-27
- Buy Stratton John G · Director 2,000 sh · ₹16.09M 2026-05-07
- Other Moreland Mary K · EXECUTIVE VICE PRESIDENT 5,314 sh · ₹46.49M 2026-04-28
- Buy Starks Daniel J · Director 10,000 sh · ₹85.86M 2026-04-27
- Award Conroy Kevin T · Director 2,286 sh 2026-04-24
- Award Stratton John G · Director 2,286 sh 2026-04-24
- Award Starks Daniel J · Director 2,286 sh 2026-04-24
Insiders must report within two business days. Sales are often pre-planned (10b5-1) rather than a signal — buys tend to say more.
What does this show?
Buys and sells by the company's own directors and officers, from their SEC filings. Insiders sell for many reasons, but clusters of open-market buying can signal confidence.
Learn more on Investopedia →Competitors
Medical Devices · tap to jumpNo competitors listed for ABT yet — sign in to add the first one.
What does this show?
A few peers in the same business, each with its own mini snowflake, so you can see how this company stacks up rather than judging it in isolation. Anyone signed in can add a missing competitor — it shows for everyone, marked as user-added.
Learn more on Investopedia →In the news
- Health Care Roundup: Market Talk
- Dexcom Shakes Off Abbott-Tied Malaise As U.S. Wearables Market Takes Off
- Can Abbott Laboratories (ABT) Stay Reasonable As Its Breakup Nears?
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGEN
- Capitol Hill's Top Trades: The Hottest Stocks Congress Is Trading Right Now
- Point-of-Care International Normalized Ratio (INR) Testing Market Report 2026 | Secure 10.1% CAGR Gains as Abbott, Roche, Danaher and Siemens Healthineers Scale Home Monitoring
- Perrigo exits infant-formula with sale to MeridianMade
- AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000
My notes
Sign in to keep a private decision journal on this stock — only you can see your notes.
Hi! I can explain Abbott's numbers — valuation, health, the dividend, the fair-value gap. What would you like to know?
Otto explains what's on this page — not investment advice.